Skip to main content
PMC home page
Journal of Epidemiology and Community Health logoLink to Journal of Epidemiology and Community Health
. 1998 Feb;52(2):111–115. doi: 10.1136/jech.52.2.111

Calculating appropriate target cancer detection rates and expected interval cancer rates for the UK NHS Breast Screening Programme. Interval Cancer Working Group

S Moss, R Blanks
PMCID: PMC1756675  PMID: 9578858

Abstract

OBJECTIVES: To enable better monitoring of interim outcome measures in the NHS Breast Screening Programme by providing revised targets for cancer detection rates, and revised expected interval cancer rates. DESIGN AND SETTING: Expected detection rates of invasive cancers at prevalent screen are calculated, using estimates of the underlying England and Wales incidence rates and age specific prevalence incidence ratios from the Swedish Two County Study. Expected interval cancer rates are also derived from this study, and are used to calculate expected detection rates at rescreening. RESULTS: The expected invasive cancer detection rates at first screen for women aged 50-52 is 3.6 per 1000. The expected rate at rescreening for women aged 53-64 is 4.0 per 1000. Expected interval cancer rates for women screened from 1995/6 onwards are 0.45 per 1000, 0.65 per 1000, and 1.2-1.3 per 1000 for the periods within 0-<12, 12-<24, and 24-<36 months of screening. CONCLUSIONS: The target cancer detection rates and expected interval cancer rates for the NHS Breast Screening Programme have been revised in the light of more recent data. Monitoring of the extent to which the programme is meeting these revised targets will give a more accurate indication of the potential to meet the Health of the Nation target of a 25% reduction in breast cancer mortality by the year 2000.

 

Full Text

The Full Text of this article is available as a PDF (92.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blanks R. G., Day N. E., Moss S. M. Monitoring the performance of breast screening programmes: use of indirect standardisation in evaluating the invasive cancer detection rate. J Med Screen. 1996;3(2):79–81. doi: 10.1177/096914139600300206. [DOI] [PubMed] [Google Scholar]
  2. Blanks R. G., Moss S. M. Monitoring the performance of breast screening programmes: allowing for geographical variation in breast cancer incidence. J Med Screen. 1996;3(2):82–84. doi: 10.1177/096914139600300207. [DOI] [PubMed] [Google Scholar]
  3. Day N. E., Williams D. R., Khaw K. T. Breast cancer screening programmes: the development of a monitoring and evaluation system. Br J Cancer. 1989 Jun;59(6):954–958. doi: 10.1038/bjc.1989.203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Day N., McCann J., Camilleri-Ferrante C., Britton P., Hurst G., Cush S., Duffy S. Monitoring interval cancers in breast screening programmes: the east Anglian experience. Quality Assurance Management Group of the East Anglian Breast Screening Programme. J Med Screen. 1995;2(4):180–185. doi: 10.1177/096914139500200402. [DOI] [PubMed] [Google Scholar]
  5. Duffy S. W., Tabar L., Fagerberg G., Gad A., Gröntoft O., South M. C., Day N. E. Breast screening, prognostic factors and survival--results from the Swedish two county study. Br J Cancer. 1991 Dec;64(6):1133–1138. doi: 10.1038/bjc.1991.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Frisell J., Eklund G., Hellström L., Somell A. Analysis of interval breast carcinomas in a randomized screening trial in Stockholm. Breast Cancer Res Treat. 1987;9(3):219–225. doi: 10.1007/BF01806383. [DOI] [PubMed] [Google Scholar]
  7. Ikeda D. M., Andersson I., Wattsgård C., Janzon L., Linell F. Interval carcinomas in the Malmö Mammographic Screening Trial: radiographic appearance and prognostic considerations. AJR Am J Roentgenol. 1992 Aug;159(2):287–294. doi: 10.2214/ajr.159.2.1632342. [DOI] [PubMed] [Google Scholar]
  8. Moss S. M., Michel M., Patnick J., Johns L., Blanks R., Chamberlain J. Results from the NHS breast screening programme 1990-1993. J Med Screen. 1995;2(4):186–190. doi: 10.1177/096914139500200403. [DOI] [PubMed] [Google Scholar]
  9. Prior P., Woodman C. B., Wilson S., Threlfall A. G. Reliability of underlying incidence rates for estimating the effect and efficiency of screening for breast cancer. J Med Screen. 1996;3(3):119–122. doi: 10.1177/096914139600300303. [DOI] [PubMed] [Google Scholar]
  10. Tabár L., Faberberg G., Day N. E., Holmberg L. What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer. 1987 May;55(5):547–551. doi: 10.1038/bjc.1987.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Tabár L., Fagerberg C. J., Gad A., Baldetorp L., Holmberg L. H., Gröntoft O., Ljungquist U., Lundström B., Månson J. C., Eklund G. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet. 1985 Apr 13;1(8433):829–832. doi: 10.1016/s0140-6736(85)92204-4. [DOI] [PubMed] [Google Scholar]
  12. Wald N. J., Murphy P., Major P., Parkes C., Townsend J., Frost C. UKCCCR multicentre randomised controlled trial of one and two view mammography in breast cancer screening. BMJ. 1995 Nov 4;311(7014):1189–1193. doi: 10.1136/bmj.311.7014.1189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Woodman C. B., Threlfall A. G., Boggis C. R., Prior P. Is the three year breast screening interval too long? Occurrence of interval cancers in NHS breast screening programme's north western region. BMJ. 1995 Jan 28;310(6974):224–226. doi: 10.1136/bmj.310.6974.224. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Epidemiology and Community Health are provided here courtesy of BMJ Publishing Group

RESOURCES